Bicycle Therapeutics (BCYC) Revenue (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Revenue came in at $629000.0 in Q2 2026, down 78.46% YoY from $2.9 million in Q2 2025, and down 29.09% on a QoQ basis from $887000.0 in Q1 2026.
Bicycle Therapeutics (BCYC) Revenue (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Revenue data on file, last reported at $629000.0 in Q2 2026.
- Quarterly Revenue fell 78.46% year-over-year to $629000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $61.2 million (up 217.44% YoY) and the FY2025 annual result came in at $72.6 million, up 105.77% from the prior year.
- Revenue fell to $629000.0 in Q2 2026, from $887000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $48.0 million in Q4 2025 to a low of $629000.0 in Q2 2026.
- A 5-year average of $8.4 million and a median of $5.3 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2025 — Revenue jumped 1193.28% — and 2026, when it sank 91.11%.
- Tracing BCYC's Revenue over 5 years: stood at $8.4 million in 2022, then plunged by 36.54% to $5.3 million in 2023, then plunged by 30.44% to $3.7 million in 2024, then jumped by 1193.28% to $48.0 million in 2025, then slumped by 98.69% to $629000.0 in 2026.
- The last three Revenue figures came in at $629000.0 (Q2 2026), $887000.0 (Q1 2026), and $48.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | 629,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 629,000.00 |
| Mar 31, 2026 | 887,000.00 |
| Dec 31, 2025 | 47.96 Mn |
| Sep 30, 2025 | 11.73 Mn |
| Jun 30, 2025 | 2.92 Mn |
| Mar 31, 2025 | 9.98 Mn |
| Dec 31, 2024 | 3.71 Mn |
| Sep 30, 2024 | 2.68 Mn |
| Jun 30, 2024 | 9.36 Mn |
| Mar 31, 2024 | 10.40 Mn |
| Dec 31, 2023 | 5.33 Mn |
| Sep 30, 2023 | 5.35 Mn |
| Jun 30, 2023 | 11.40 Mn |
| Mar 31, 2023 | 4.90 Mn |
| Dec 31, 2022 | 8.40 Mn |
| Sep 30, 2022 | 3.04 Mn |
| Jun 30, 2022 | 5.30 Mn |
| Mar 31, 2022 | 3.86 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | 4.33 Mn |